General Information
In-person or via LIVE webcast...the CEC difference!
If you are still deciding on whether to attend in-person, CEC provides the ability to Register NOW / Pay LATER, live-stream access from your room, and more. If you are unable to travel, you can still earn live CME credit virtually via our LIVE streaming webcast. Whether you attend in person or watch via webcast, all lectures will be recorded and made available to participants for 30 days. Learn more about what makes the CEC conference experience different from the rest »
26th Annual Hypertension, Diabetes & Dyslipidemia Conference (15.25 CREDITS)
June 23-25, 2022
Charleston Gaillard Center
Charleston, South Carolina
Earn a total of 30.25 credits with our Special CME Offer! Attend the 26th Annual Hypertension, Diabetes & Dyslipidemia Conference (15.25 CME Credits) and you will receive a FREE ($499 value) online 15.25 credit CME course from CME365™.* Register now »
*Offer valid only for in-person participants of the live 26th Annual Hypertension, Diabetes & Dyslipidemia Conference. Access to the online CME course will be sent to registrants after they have attended and successfully completed the conference. The online CME course is not transferable. This offer is not valid if you cancel your registration or are a no show at the live conference. Webcast participants as well as in-person participants who have paid a partial conference fee are not eligible for this offer.
Unable to travel to Charleston? No worries! Join the LIVE CME conference webcast and receive the same number of credits (15.25) as if you attended the conference in person. More webcast details...
Overview
This three day intensive conference, held on June 23-25, 2022 in Charleston, South Carolina, addresses all the issues confronting clinicians who treat challenging patients with diabetes, hypertension, and dyslipidemia and how to apply this knowledge to everyday practice.
Over the past several years controversies in the appropriate target for Hemoglobin A1C, BP, and LDL-Cholesterol on outcome improvement continue to occur in Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Despite the results from the ACCORD, VADT, and ADVANCE studies suggesting the benefits of reducing A1C on macrovascular disease with a more intensive strategy remains unclear, and even harmful, individualized A1C targets for those with newly diagnosed diabetes are often recommended. In addition, controversy continues to exist in cholesterol control as recent guidelines suggest that one should decide on the intensity of statin-based therapy in those at risk for or with established ASCVD rather than a specific LDL-cholesterol goal to improve clinical outcome. Finally, the recent SPRINT trial found that lower targets for BP reduction can and should be achieved in high-risk adults with hypertension.
This conference will address these and other issues confronting the clinician who treats challenging patients with diabetes, hypertension, and dyslipidemia. The participant will learn the most current information on these issues and will be able to apply these important clinical principles back to their everyday practice to improve the care of their patients.
Program Objectives
As a result of this educational activity, participants should be better able to:
- Formulate an efficient and effective assessment and monitoring plan of a patient's condition as it relates to hypertension, diabetes, and dyslipidemia.
- Utilize current guidelines in the diagnosis and management of diabetes, hypertension, and dyslipidemia.
- Develop individualized interventions and treatment strategies for patients presenting with hypertension, diabetes, and/or dyslipidemia that will translate into improved long-term outcomes.
Target Audience
This activity is designed for physicians specializing in Internal Medicine, Family Medicine, Geriatric Medicine, Endocrinology, Lipidology and Hypertension. Health care clinicians including physician assistants and nurse practitioners specializing in these areas or those managing patients with Hypertension, Diabetes, and/or Hyperlipidemia, alone or in combination, may benefit from this activity.